Pharma
-
Zanidatamab’s Dual-Targeting Design Offers Alternative To Trastuzumab Deruxtecan
Zanidatamab’s unique mechanism and clinical data show promise for HER2-positive cancer treatment
-
FDA expands Anktiva approval to cover papillary-only bladder cancer, first treatment for this group
The FDA has broadened Anktiva’s use with BCG to include patients with BCG-unresponsive, high-grade papillary-only non-muscle-invasive bladder cancer, offering a bladder-preserving option…
-
ALS Patient Improves, Still Works as Physician After RNA Therapy
BETHESDA, September 19 — A man with a rare, inherited form of amyotrophic lateral sclerosis has become the first person to receive…
-
PAHO Opens HIV Prevention Injection Access for Fourteen Nations
WASHINGTON, September 15 — The Pan American Health Organization announced a new pathway on Tuesday that will let 14 countries in Latin…
-
Fenfluramine: From Fen-Phen scandal to seizure drug
NEW YORK, July 22 — Fenfluramine is back on the American market, a comeback twenty-three years in the making. The same drug…
-
Ernexa Therapeutics Advances Cancer Therapy Candidate to Phase 1 Trials
SAN FRANCISCO, July 15 — Ernexa Therapeutics, a biotechnology company operating in the U.S. healthcare sector, is preparing to advance its lead…
-
Ernexa Therapeutics Initiates Steps for ERNA-101 Clinical Trials
KARACHI, July 15 — Ernexa Therapeutics is moving toward a planned first-in-human Phase 1 study for its lead cancer candidate, ERNA-101, though…
-
Ernexa Therapeutics targets 2026 for first-in-human cancer trial
NEW YORK, July 15 — Ernexa Therapeutics is moving its lead candidate ERNA-101 toward a first-in-human Phase 1 study, with the trial…
-
Ernexa Therapeutics Advances ERNA-101 to First-in-Human Trial Planning
SINGAPORE, July 15 — A new cancer therapy candidate is taking its first step from the laboratory bench toward the bedside, with…
-
Akeso’s Cadonilimab trial expands into US for new cancer treatment
ISLAMABAD, July 15 — Akeso, the Chinese biopharmaceutical company, has advanced its investigational drug cadonilimab into a Phase II clinical trial in…
-
Metformin TAME Trial Tests Diabetes Drug for Anti-Aging Effects
NEW YORK, July 14 — A decades-old diabetes drug is now at the center of one of the most strategically significant aging…
-
FDA’s critical decision looms on full approval for Alzheimer’s drug
WASHINGTON, July 14 — The U.S. Food and Drug Administration granted accelerated approval to lecanemab, marketed as Leqembi, on January 6, 2023,…
-
China’s Pharma Surge Accelerates Global Drug Development Deals
BEIJING, July 13 — Cross-border deals for innovative drugs originating from China have reached a record US$110 billion in the first half…
-
Academic Pioneers to Pharma Giants Drive CAR-T Therapy
PHILADELPHIA, July 7, 2026 — Dr. Carl June, director of the Center for Cellular Immunotherapies at the University of Pennsylvania, is widely…
-
CAR-T Therapy Market: Leaders, Sales, and Global Reach in 2023
ISLAMABAD, July 7 — The global market for CAR-T cell therapy, a personalized cancer treatment that reprograms a patient’s own immune cells…
-
Targeted Therapies Dominate Renal Cancer Drug Pipeline Through 2026
NEW YORK, July 3 — A comprehensive report on the renal cancer pipeline for 2026 has identified over 80 pipeline drugs and…
-
ASCO 2026 insights spotlight hurdles in refining oncology trial designs
TORONTO, July 2 — Oncology experts are set to gather for a free webinar hosted by Xtalks, focusing on how data from…
-
Global Oncology Precision Medicine Market Set for Robust Expansion Through 2031
GLOBAL — July 1, 2026 — The global market for oncology precision medicine is opening up fresh opportunities in diagnostics and therapeutics,…
-
South Korea Grants Anixa Biosciences Strong Patent for Breast Cancer Vaccine
South Korea just gave a California biotech firm a patent that runs until 2040. That matters for women in Central Asia. The…
-
Ipsen acquires Kartos, advancing navtemadlin trial for myelofibrosis patients
The clinical trial is called POIESIS. More than 600 patients. Over 250 sites worldwide. It is testing navtemadlin as an add-on to…
-
Takeda’s Oveporexton Shows Promise for Narcolepsy Treatment in Trials Completed
In July 2025, Takeda announced that its experimental wake‑promoting drug, oveporexton, successfully completed phase 3 clinical testing for narcolepsy. The trial results…
-
New Weight-Loss Drug Mazdutide Shows Promising Results In Late Trials
A collaborative effort between U.S. drugmaker Eli Lilly and Chinese biotech Innovent Biologics has produced mazdutile, a once‑weekly injectable designed to address…
-
GLP-1 Receptor Agonists Show Promise in Diabetes and Obesity Treatment
As of March 25, 2025, a class of drugs called GLP-1 receptor agonists continues to gain attention for their expanding role in…
-
Nivolumab/hyaluronidase approved in US for cancer treatment
United States, December 20, 2024 — infopulsetoday.com — Nivolumab/hyaluronidase, a newly approved anti-cancer medication, has been cleared for medical use in the…
Most read
-
Minnesota Makes Personal Finance Course Mandatory for High School Graduation
-
UK Households With £10,000 Risk Losing £300 To Low Interest Rates
-
Selangor International Care Expo in Kuala Lumpur 2026
-
Asian & Oceanian Epilepsy Congress 2026 in Kuala Lumpur
-
Baby & Beyond Maternity Expo in Kuala Lumpur 2026
-
Why Long COVID Raises Hypertension Risk and How to Monitor Your Blood Pressure
-
Amgen and AstraZeneca Combination Therapy Shows Unprecedented Survival Gains in Lung Cancer
-
Moderna’s mRNA Platform Enables Rapid Personalized Cancer Vaccines
-
Evaluating Skyrizi’s Efficacy and Market Position in Crohn’s Disease Care
-
How Personalized mRNA Vaccines Target Neoantigens to Beat Melanoma
-
Nationwide Rate Boost: How Rising Cash ISA Yields Beat Inflation Without Long-Term Lock-Ins
-
Estate Taxes Hit Retirees Selling High-Value Art: Navigating Double Taxation Risks
-
How Revolving Credit Card Balances Drive Industry Profits and Stifle Budgets
-
Why Medicare Documentation Rules Drive Denied Claims for Diabetic Shoes
-
Suze Orman: Why Medical Costs Demand an 8-Month Emergency Fund
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
Understanding the FDA’s Accelerated Approval of Iberdomide for Multiple Myeloma
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
Personalized mRNA Cancer Vaccine Succeeds in First Phase 3 Melanoma Trial
-
Dennis Lo Pioneers Liquid Biopsy for Cancer and Prenatal Testing
-
New Research Highlights Rising Internet Addiction Debate
-
Study Suggests Drinking Water With Meals May Lead To Overeating
-
Real-World Oncotype DX Adoption: Rates and Key Challenges
-
Energy Drinks: Youth Marketing, Caffeine Risks Under Scrutiny
-
ADHD Dopamine Dysfunction Disrupts Sleep-Wake Cycles, Study Finds